The effects of methylphenidate and atomoxetine on epigenetic DNA modifiers in an in vitro model of human peripheral blood mononuclear cells
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Attention-deficit hyperactivity disorder (ADHD) is a childhood neurodevelopmental disorder affecting approximately 5%–8% of children. Adults with persistent childhood-onset ADHD have twice the risk of developing substance use disorder (SUD) compared to those without ADHD. While various drugs can cause epigenetic modifications, it remains unknown how methylphenidate (MPH), the first-line treatment option for ADHD, and atomoxetine (ATX), which is used when stimulant drugs are ineffective or not tolerated, influence DNA methylation. In this study, we examined the concentration-dependent effect of MPH and ATX on DNA methyltransferases (DNMTs) and ten-eleven translocation enzymes (TETs) in an in vitro model of human peripheral blood mononuclear cells (PBMCs). We also assessed whether pre-exposure to MPH or ATX could sensitize PBMCs to subsequent cocaine exposure. We showed that repeated exposure to MPH or ATX did not affect the mRNA levels or enzymatic activity of DNMTs or TETs in vitro in PBMCs. In addition, prior repeated MPH or ATX exposure did not sensitize PBMCs to subsequent cocaine treatment. These findings suggest that short-term repeated exposure to either MPH or ATX does not significantly impact the expression or activity of epigenetic DNA modifiers in PBMCs. This does not exclude the possibility of long-term or brain-specific effects on DNA methylation.
Fields of Study & Subjects
Attention Deficit Hyperactivity Disorder
Epigenetics and DNA Methylation
Neurotransmitter Receptor Influence on Behavior
Publication details
- Journal / source
- Epigenetics Reports
- Volume
- 4
- Issue
- 1
- Publication date
- 28 March 2026
- Language
- EN